A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease

Exclusion Criteria

• •Treatment with tetrandrine or other antifibrotic drugs within 1 month before screening
• •Diabetes with fasting blood glucose greater than 11.1 mmol per L
• •Resting arterial oxygen partial pressure less than 50 mmHg
• •Active peptic ulcers or bleeding disorders
• •Tumors with expected survival less than 1 year
• •Active pulmonary tuberculosis
• •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 5 times the upper limit of normal (ULN) or higher, or ALT or AST 3 times ULN or higher with total bilirubin 2 times ULN or higher
• •Creatinine clearance less than 30 mL per min (per Cockcroft-Gault formula) or patients receiving dialysis
• •Known allergy to tetrandrine or its excipients
• •Severe psychological, mental, cognitive, or intellectual impairments that may affect compliance
• •Pregnant or breastfeeding women, or those planning pregnancy within 3 months after the last study drug dose
• •Participation in another clinical trial within 3 months before screening
• •Patients deemed unsuitable for the study by the investigator
• •Clinically significant environmental exposure history that may cause pulmonary fibrosis (e.g., amiodarone, asbestos, beryllium, radiation)